PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
224 hedge funds and large institutions have $1.17B invested in PDL BioPharma, Inc. in 2013 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 93 increasing their positions, 59 reducing their positions, and 27 closing their positions.
265% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $3.4M
58% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 59
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
9% more capital invested
Capital invested by funds: $1.08B → $1.17B (+$93.2M)
6% more funds holding
Funds holding: 212 → 224 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$14.5M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.19M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.66M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.78M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$5.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$9.53M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$8.24M |
| 3 |
Two Sigma Investments
New York
|
-$7.8M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$6.62M |
| 5 |
Two Sigma Advisers
New York
|
-$5.4M |
PDLI Hedge Fund Activity: Q4 2013 in Review
224 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2013, worth a combined $1.17B — up 8.7% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PDLI positions and 27 closed out — a net gain of 12 holders — while 93 added to existing stakes and 59 trimmed.
The largest buyer was Numeric Investors, adding an estimated $14.5M. The largest seller was Hussman Strategic Advisors, cutting an estimated $9.53M.
- 224 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2013, up from 212 in Q3 2013.
- Funds reported $1.17B of PDL BioPharma, Inc. stock for Q4 2013, up 8.7% quarter-over-quarter.
- 39 funds opened new PDL BioPharma, Inc. positions in Q4 2013 and 27 closed out, a net change of +12 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2013 was Numeric Investors, an estimated $14.5M added.
- The largest PDL BioPharma, Inc. seller in Q4 2013 was Hussman Strategic Advisors, an estimated $9.53M sold.
Based on aggregated 13F filings for Q4 2013.